Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM.

Blood. 2004 Jun 1;103(11):4243-50. Epub 2004 Feb 24.


Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.

Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA.

Blood. 2007 Feb 15;109(4):1687-91. Epub 2006 Nov 7.


Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells.

Ingram DA, Wenning MJ, Shannon K, Clapp DW.

Blood. 2003 Mar 1;101(5):1984-6. Epub 2002 Oct 17.


In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.

Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM.

Blood. 1999 Oct 1;94(7):2469-76.


Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia.

Gitler AD, Kong Y, Choi JK, Zhu Y, Pear WS, Epstein JA.

Pediatr Res. 2004 Apr;55(4):581-4. Epub 2004 Jan 22.


Nf1 and Gmcsf interact in myeloid leukemogenesis.

Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM.

Mol Cell. 2000 Jan;5(1):189-95.


Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.

Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW.

J Exp Med. 1998 Jun 1;187(11):1893-902.


Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.

Largaespada DA, Brannan CI, Jenkins NA, Copeland NG.

Nat Genet. 1996 Feb;12(2):137-43.


Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro.

Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, Wenning MJ, Diaz B, Travers JB, Hood A, Marshall M, Williams DA, Clapp DW.

J Exp Med. 2001 Jul 2;194(1):57-69.


The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1.

Zhu C, Saberwal G, Lu Y, Platanias LC, Eklund EA.

J Biol Chem. 2004 Dec 3;279(49):50874-85. Epub 2004 Sep 14.


Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.


Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K.

Nat Genet. 1996 Feb;12(2):144-8.


Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.

Cutts BA, Sjogren AK, Andersson KM, Wahlstrom AM, Karlsson C, Swolin B, Bergo MO.

Blood. 2009 Oct 22;114(17):3629-32. doi: 10.1182/blood-2009-02-205146. Epub 2009 Aug 26.


Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells.

Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW.

J Biol Chem. 2001 Mar 9;276(10):7240-5. Epub 2000 Nov 15.


Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC.

J Bone Miner Res. 2013 Dec;28(12):2476-89. doi: 10.1002/jbmr.1992.


A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.

Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA.

Blood. 2009 Jan 29;113(5):1075-85. doi: 10.1182/blood-2008-03-144436. Epub 2008 Oct 23.


Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K.

J Clin Invest. 2013 Jan;123(1):335-9. doi: 10.1172/JCI63193. Epub 2012 Dec 10.


Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.

Lauchle JO, Braun BS, Loh ML, Shannon K.

Pediatr Blood Cancer. 2006 May 1;46(5):579-85. Review.


Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.

Wiesner SM, Geurts JL, Diers MD, Bergerson RJ, Hasz DE, Morgan KJ, Largaespada DA.

Am J Hematol. 2011 Jul;86(7):579-85. doi: 10.1002/ajh.22035.


NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.

Xu J, Ismat FA, Wang T, Yang J, Epstein JA.

Circulation. 2007 Nov 6;116(19):2148-56. Epub 2007 Oct 22.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk